{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:38:20Z","timestamp":1785839900167,"version":"3.56.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health Commission Project of Henan Province, P.R. China","award":["No. 2221023101010; No.242102311116; No.212102310205"],"award-info":[{"award-number":["No. 2221023101010; No.242102311116; No.212102310205"]}]},{"name":"Overseas Training Program for Medical and Health Science and Technology Talents, which was jointly launched by Henan Provincial Health Commission and Henan Academy of Medical Sciences","award":["HNMOT2024038"],"award-info":[{"award-number":["HNMOT2024038"]}]},{"name":"The \u2018Three 100s\u2019 Project of Henan Provincial Department of Science and Technology and Henan Provincial Medical College, P.R. China","award":["No. H20240205"],"award-info":[{"award-number":["No. H20240205"]}]},{"name":"Health Technology Innovation Out-standing Youth Talent Training Project of Henan Province","award":["No. JQRC2023014"],"award-info":[{"award-number":["No. JQRC2023014"]}]},{"name":"Medical Science and Technology Research Program Jointly Established Project of Henan Province, P.R. China","award":["No. LHGJ20230016; No. LHGJ20230023"],"award-info":[{"award-number":["No. LHGJ20230016; No. LHGJ20230023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study utilized TCGA database to explore the role of m6A modification and immune infiltration in AML. Through unsupervised clustering and WGCNA analysis, 8 hub genes were identified, and a risk model with\n                    <jats:italic>EHBP1L1<\/jats:italic>\n                    and\n                    <jats:italic>ZNF385A<\/jats:italic>\n                    was established using LASSO regression. A nomogram incorporating hub gene risk score and age showed satisfactory prognostic prediction. External validation of GEO confirmed the model\u2019s effectiveness. TME analysis revealed correlations with monocytes and Treg cells, while immune checkpoints and HLA genes were associated with risk scores. Drug sensitivity analysis suggested potential responses to specific chemotherapy drugs. TIDE analysis indicated reduced ICI treatment benefit in high-risk patients. RT-qPCR validations revealed the significance of prognosis and risk stratification of\n                    <jats:italic>ZNF385A<\/jats:italic>\n                    . The noticeable trend of\n                    <jats:italic>EHBP1L1<\/jats:italic>\n                    was observed. In addition, the accurate predictive capability of the risk model has been validated by clinical samples. Therefore, the risk model enables a quantitative evaluation of disease severity and progression risk in AML patients, based on their clinical and biological characteristics. This precise prediction not only informs treatment decisions but also guides the selection of chemotherapy regimens, overall improving patient outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-22002-5","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:50:13Z","timestamp":1762159813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of a m6A-immune-related risk model for predicting prognosis, immune microenvironment, and drug responses in acute myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Yanliang","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"5","key":"22002_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea, D. A. et al. Acute myeloid leukemia, Version 3.2023, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 21(5), 503\u2013513. https:\/\/doi.org\/10.6004\/jnccn.2023.0025 (2023).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"22002_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.770451","author":"D Li","year":"2021","unstructured":"Li, D. et al. Identification of m6A-related lncRNAs associated with prognoses and immune responses in acute myeloid leukemia. Front. Cell Dev. Biol. https:\/\/doi.org\/10.3389\/fcell.2021.770451 (2021).","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"22002_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ymthe.2019.12.014","volume":"28","author":"YA Yeung","year":"2020","unstructured":"Yeung, Y. A. et al. An optimized full-length FLT3\/CD3 bispecific antibody demonstrates potent anti-leukemia activity and reversible hematological toxicity. Mol. Ther. 28(3), 889\u2013900. https:\/\/doi.org\/10.1016\/j.ymthe.2019.12.014 (2020).","journal-title":"Mol. Ther."},{"key":"22002_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00293-w","author":"X Zheng","year":"2021","unstructured":"Zheng, X. & Gong, Y. Functions of RNA N6-methyladenosine modification in acute myeloid leukemia. Biomark. Res. https:\/\/doi.org\/10.1186\/s40364-021-00293-w (2021).","journal-title":"Biomark. Res."},{"key":"22002_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.04.001","author":"K Liu","year":"2022","unstructured":"Liu, K. et al. Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment. Mol. Ther. Nucleic Acids https:\/\/doi.org\/10.1016\/j.omtn.2022.04.001 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4","key":"22002_CR6","doi-asserted-by":"publisher","first-page":"e1628","DOI":"10.1002\/ctm2.1628","volume":"14","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clin. Transl. Med. 14(4), e1628. https:\/\/doi.org\/10.1002\/ctm2.1628 (2024).","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"22002_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-024-01546-5","volume":"17","author":"G Feng","year":"2024","unstructured":"Feng, G. et al. Small molecule inhibitors targeting m6A regulators. J. Hematol. Oncol. 17(1), 30. https:\/\/doi.org\/10.1186\/s13045-024-01546-5 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"22002_CR8","doi-asserted-by":"publisher","first-page":"1281687","DOI":"10.3389\/fimmu.2023.1281687","volume":"14","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia. Front. Immunol. 14, 1281687. https:\/\/doi.org\/10.3389\/fimmu.2023.1281687 (2023).","journal-title":"Front. Immunol."},{"key":"22002_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00480-z","author":"W Zhou","year":"2024","unstructured":"Zhou, W. et al. A novel AML1-ETO\/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia. Exp. Hematol. Oncol. https:\/\/doi.org\/10.1186\/s40164-024-00480-z (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"22002_CR10","doi-asserted-by":"publisher","first-page":"117783","DOI":"10.1016\/j.envres.2023.117783","volume":"244","author":"R Kou","year":"2024","unstructured":"Kou, R. et al. Exosome-shuttled FTO from BM-MSCs contributes to cancer malignancy and chemoresistance in acute myeloid leukemia by inducing m6A-demethylation: A nano-based investigation. Environ. Res. 244, 117783. https:\/\/doi.org\/10.1016\/j.envres.2023.117783 (2024).","journal-title":"Environ. Res."},{"issue":"1","key":"22002_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40364-023-00464-x","volume":"11","author":"R Li","year":"2023","unstructured":"Li, R. et al. RNA demethylase ALKBH5 promotes tumorigenesis of t (8;21) acute myeloid leukemia via ITPA m6A modification. Biomark. Res. 11(1), 30. https:\/\/doi.org\/10.1186\/s40364-023-00464-x (2023).","journal-title":"Biomark. Res."},{"issue":"8","key":"22002_CR12","doi-asserted-by":"publisher","first-page":"105055","DOI":"10.1016\/j.jbc.2023.105055","volume":"299","author":"P Wang","year":"2023","unstructured":"Wang, P. et al. Deubiquitinase USP9X stabilizes RNA m6A demethylase ALKBH5 and promotes acute myeloid leukemia cell survival. J. Biol. Chem. 299(8), 105055. https:\/\/doi.org\/10.1016\/j.jbc.2023.105055 (2023).","journal-title":"J. Biol. Chem."},{"issue":"12","key":"22002_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41419-023-06325-7","volume":"14","author":"X Liao","year":"2023","unstructured":"Liao, X. et al. Deletion of Mettl3 in mesenchymal stem cells promotes acute myeloid leukemia resistance to chemotherapy. Cell. Death Dis. 14(12), 796. https:\/\/doi.org\/10.1038\/s41419-023-06325-7 (2023).","journal-title":"Cell. Death Dis."},{"issue":"1","key":"22002_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.gendis.2023.01.016","volume":"11","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z. et al. RNA m6A reader YTHDF2 facilitates precursor miR-126 maturation to promote acute myeloid leukemia progression. Genes Dis. 11(1), 382\u2013396. https:\/\/doi.org\/10.1016\/j.gendis.2023.01.016 (2024).","journal-title":"Genes Dis."},{"key":"22002_CR15","doi-asserted-by":"publisher","first-page":"123990","DOI":"10.1016\/j.ijbiomac.2023.123990","volume":"237","author":"C Wu","year":"2023","unstructured":"Wu, C., Cui, J., Huo, Y., Shi, L. & Wang, C. Alternative splicing of HOXB-AS3 underlie the promoting effect of nuclear m6A reader YTHDC1 on the self-renewal of leukemic stem cells in acute myeloid leukemia. Int. J. Biol. Macromol. 237, 123990. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.123990 (2023).","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"22002_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41590-020-0650-4","volume":"21","author":"Z Shulman","year":"2020","unstructured":"Shulman, Z. & Stern-Ginossar, N. The RNA modification N6-methyladenosine as a novel regulator of the immune system. Nat. Immunol. 21(5), 501\u2013512. https:\/\/doi.org\/10.1038\/s41590-020-0650-4 (2020).","journal-title":"Nat. Immunol."},{"key":"22002_CR17","doi-asserted-by":"publisher","first-page":"6327614","DOI":"10.1155\/2020\/6327614","volume":"2020","author":"Y-N Wang","year":"2020","unstructured":"Wang, Y.-N., Yu, C.-Y. & Jin, H.-Z. RNA N6-methyladenosine modifications and the immune response. J. Immunol. Res. 2020, 6327614. https:\/\/doi.org\/10.1155\/2020\/6327614 (2020).","journal-title":"J. Immunol. Res."},{"key":"22002_CR18","doi-asserted-by":"publisher","first-page":"912526","DOI":"10.3389\/fimmu.2022.912526","volume":"13","author":"X Ouyang","year":"2022","unstructured":"Ouyang, X. & Gong, Y. One stone, two birds: N6-methyladenosine RNA Modification in leukemia stem cells and the tumor immune microenvironment in acute myeloid leukemia. Front. Immunol. 13, 912526. https:\/\/doi.org\/10.3389\/fimmu.2022.912526 (2022).","journal-title":"Front. Immunol."},{"key":"22002_CR19","doi-asserted-by":"publisher","first-page":"1335774","DOI":"10.3389\/fimmu.2024.1335774","volume":"15","author":"W Su","year":"2024","unstructured":"Su, W., Che, L., Liao, W. & Huang, H. The RNA m6A writer METTL3 in tumor microenvironment: Emerging roles and therapeutic implications. Front. Immunol. 15, 1335774. https:\/\/doi.org\/10.3389\/fimmu.2024.1335774 (2024).","journal-title":"Front. Immunol."},{"issue":"2","key":"22002_CR20","doi-asserted-by":"publisher","first-page":"113796","DOI":"10.1016\/j.celrep.2024.113796","volume":"43","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Suppression of the METTL3-m6A-integrin \u03b21 axis by extracellular acidification impairs T cell infiltration and antitumor activity. Cell. Rep. 43(2), 113796. https:\/\/doi.org\/10.1016\/j.celrep.2024.113796 (2024).","journal-title":"Cell. Rep."},{"issue":"15","key":"22002_CR21","doi-asserted-by":"publisher","first-page":"e113126","DOI":"10.15252\/embj.2022113126","volume":"42","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. YTHDF2\/m6 A\/NF-\u03baB axis controls anti-tumor immunity by regulating intratumoral tregs. EMBO J. 42(15), e113126. https:\/\/doi.org\/10.15252\/embj.2022113126 (2023).","journal-title":"EMBO J."},{"issue":"6","key":"22002_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/0008-5472.CAN-21-4249","volume":"83","author":"Y-G Hong","year":"2023","unstructured":"Hong, Y.-G. et al. The RNA m6A reader YTHDF1 is required for acute myeloid leukemia progression. Cancer Res. 83(6), 845\u2013860. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4249 (2023).","journal-title":"Cancer Res."},{"key":"22002_CR23","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00599","author":"F Z\u00e1le\u0161\u00e1k","year":"2024","unstructured":"Z\u00e1le\u0161\u00e1k, F. et al. Structure-based design of a potent and selective YTHDC1 ligand. J. Med. Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00599 (2024).","journal-title":"J. Med. Chem."},{"key":"22002_CR24","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1016\/j.csbj.2022.11.045","volume":"20","author":"J Li","year":"2022","unstructured":"Li, J., Zhang, H. & Wang, H. N1-methyladenosine modification in cancer biology: Current status and future perspectives. Comput. Struct. Biotechnol. J. 20, 6578\u20136585. https:\/\/doi.org\/10.1016\/j.csbj.2022.11.045 (2022).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"22002_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2022.2160134","author":"X Liao","year":"2023","unstructured":"Liao, X. et al. m6A RNA methylation regulators predict prognosis and indicate characteristics of tumour microenvironment infiltration in acute myeloid leukaemia. Epigenetics https:\/\/doi.org\/10.1080\/15592294.2022.2160134 (2023).","journal-title":"Epigenetics"},{"issue":"16","key":"22002_CR26","doi-asserted-by":"publisher","first-page":"902","DOI":"10.21037\/atm-22-3858","volume":"10","author":"S Yuan","year":"2022","unstructured":"Yuan, S. et al. Analysis of m6A-related signatures associated with the tumor immune microenvironment and predict survival in acute myeloid leukemia. Ann. Transl. Med. 10(16), 902. https:\/\/doi.org\/10.21037\/atm-22-3858 (2022).","journal-title":"Ann. Transl. Med."},{"key":"22002_CR27","doi-asserted-by":"publisher","first-page":"948079","DOI":"10.3389\/fgene.2022.948079","volume":"13","author":"Z-J Xu","year":"2022","unstructured":"Xu, Z.-J. et al. m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia. Front. Genet. 13, 948079. https:\/\/doi.org\/10.3389\/fgene.2022.948079 (2022).","journal-title":"Front. Genet."},{"issue":"5","key":"22002_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/cam4.4531","volume":"11","author":"S Han","year":"2022","unstructured":"Han, S. et al. Characterization of m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia. Cancer Med. 11(5), 1413\u20131426. https:\/\/doi.org\/10.1002\/cam4.4531 (2022).","journal-title":"Cancer Med."},{"key":"22002_CR29","doi-asserted-by":"publisher","first-page":"789914","DOI":"10.3389\/fimmu.2021.789914","volume":"12","author":"A Du","year":"2021","unstructured":"Du, A. et al. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in acute myeloid leukemia. Front. Immunol. 12, 789914. https:\/\/doi.org\/10.3389\/fimmu.2021.789914 (2021).","journal-title":"Front. Immunol."},{"issue":"1","key":"22002_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-020-01170-0","volume":"19","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol. Cancer 19(1), 53. https:\/\/doi.org\/10.1186\/s12943-020-01170-0 (2020).","journal-title":"Mol. Cancer"},{"key":"22002_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 1711, 243\u2013259. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_12 (2018).","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"22002_CR32","doi-asserted-by":"publisher","first-page":"bba345","DOI":"10.1093\/bib\/bbaa345","volume":"22","author":"M Ju","year":"2021","unstructured":"Ju, M. et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Br. Bioinform. 22(4), bba345. https:\/\/doi.org\/10.1093\/bib\/bbaa345 (2021).","journal-title":"Br. Bioinform."},{"issue":"10393","key":"22002_CR33","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo, C. D., Erba, H. P., Freeman, S. D. & Wei, A. H. Acute myeloid leukaemia. Lancet 401(10393), 2073\u20132086. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3 (2023).","journal-title":"Lancet"},{"issue":"1","key":"22002_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-022-01510-2","volume":"21","author":"L-J Deng","year":"2022","unstructured":"Deng, L.-J. et al. m6A modification: Recent advances, anticancer targeted drug discovery and beyond. Mol. Cancer 21(1), 52. https:\/\/doi.org\/10.1186\/s12943-022-01510-2 (2022).","journal-title":"Mol. Cancer"},{"issue":"1","key":"22002_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12943-023-01841-8","volume":"22","author":"S-W Yue","year":"2023","unstructured":"Yue, S.-W. et al. m6A-regulated tumor glycolysis: New advances in epigenetics and metabolism. Mol. Cancer 22(1), 137. https:\/\/doi.org\/10.1186\/s12943-023-01841-8 (2023).","journal-title":"Mol. Cancer"},{"issue":"1","key":"22002_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12943-019-1033-z","volume":"18","author":"X-Y Chen","year":"2019","unstructured":"Chen, X.-Y., Zhang, J. & Zhu, J.-S. The role of m6A RNA methylation in human cancer. Mol. Cancer. 18(1), 103. https:\/\/doi.org\/10.1186\/s12943-019-1033-z (2019).","journal-title":"Mol. Cancer."},{"issue":"4","key":"22002_CR37","doi-asserted-by":"publisher","first-page":"C762","DOI":"10.1152\/ajpcell.00212.2019","volume":"317","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA. Am. J. Physiol. Cell. Physiol. 317(4), C762\u2013C775. https:\/\/doi.org\/10.1152\/ajpcell.00212.2019 (2019).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"issue":"1","key":"22002_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12967-021-02918-y","volume":"19","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Potential roles of N6-methyladenosine (m6A) in immune cells. J. Transl. Med. 19(1), 251. https:\/\/doi.org\/10.1186\/s12967-021-02918-y (2021).","journal-title":"J. Transl. Med."},{"issue":"3","key":"22002_CR39","doi-asserted-by":"publisher","first-page":"674","DOI":"10.20517\/cdr.2023.39","volume":"6","author":"L Gurska","year":"2023","unstructured":"Gurska, L. & Gritsman, K. Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia. Cancer Drug Resist. 6(3), 674\u2013687. https:\/\/doi.org\/10.20517\/cdr.2023.39 (2023).","journal-title":"Cancer Drug Resist."},{"issue":"4","key":"22002_CR40","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago, L. & Gojo, I. Immune escape and immunotherapy of acute myeloid leukemia. J. Clin. Invest. 130(4), 1552\u20131564. https:\/\/doi.org\/10.1172\/JCI129204 (2020).","journal-title":"J. Clin. Invest."},{"issue":"1","key":"22002_CR41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12964-023-01282-2","volume":"21","author":"M Bakhtiyari","year":"2023","unstructured":"Bakhtiyari, M. et al. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: Immune checkpoints, metabolic checkpoints, and signaling pathways. Cell Commun. Signal. 21(1), 252. https:\/\/doi.org\/10.1186\/s12964-023-01282-2 (2023).","journal-title":"Cell Commun. Signal."},{"issue":"7","key":"22002_CR42","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/bcj.2015.58","volume":"5","author":"Y Kong","year":"2015","unstructured":"Kong, Y. et al. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 5(7), e330. https:\/\/doi.org\/10.1038\/bcj.2015.58 (2015).","journal-title":"Blood Cancer J."},{"key":"22002_CR43","doi-asserted-by":"publisher","first-page":"882531","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M G\u00f3mez-Llobell","year":"2022","unstructured":"G\u00f3mez-Llobell, M., Peleteiro Ra\u00edndo, A., Climent Medina, J., G\u00f3mez Centuri\u00f3n, I. & Mosquera, O. A. Immune checkpoint inhibitors in acute myeloid leukemia: A meta-analysis. Front. Oncol. 12, 882531. https:\/\/doi.org\/10.3389\/fonc.2022.882531 (2022).","journal-title":"Front. Oncol."},{"issue":"1","key":"22002_CR44","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang, R. et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat. Commun. 12(1), 832. https:\/\/doi.org\/10.1038\/s41467-021-21099-2 (2021).","journal-title":"Nat. Commun."},{"issue":"1","key":"22002_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","volume":"13","author":"C Chen","year":"2020","unstructured":"Chen, C. et al. Expression patterns of immune checkpoints in acute myeloid leukemia. J. Hematol. Oncol. 13(1), 28. https:\/\/doi.org\/10.1186\/s13045-020-00853-x (2020).","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"22002_CR46","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","volume":"10","author":"Y Lv","year":"2023","unstructured":"Lv, Y., Ma, X., Ma, Y., Du, Y. & Feng, J. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). Genes Dis. 10(6), 2366\u20132382. https:\/\/doi.org\/10.1016\/j.gendis.2022.05.020 (2023).","journal-title":"Genes Dis."},{"issue":"11","key":"22002_CR47","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","volume":"27","author":"EI Lichtman","year":"2021","unstructured":"Lichtman, E. I. et al. Preclinical evaluation of B7\u2013H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Clin. Cancer Res. 27(11), 3141\u20133153. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2540 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"22002_CR48","doi-asserted-by":"publisher","first-page":"7831","DOI":"10.1002\/cam4.4284","volume":"10","author":"L-Y Zhang","year":"2021","unstructured":"Zhang, L.-Y. et al. Integrated analysis reveals distinct molecular, clinical, and immunological features of B7\u2013H3 in acute myeloid leukemia. Cancer Med. 10(21), 7831\u20137846. https:\/\/doi.org\/10.1002\/cam4.4284 (2021).","journal-title":"Cancer Med."},{"issue":"24","key":"22002_CR49","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial. Blood 135(24), 2137\u20132145. https:\/\/doi.org\/10.1182\/blood.2020004856 (2020).","journal-title":"Blood"},{"issue":"10","key":"22002_CR50","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24(10), 1550\u20131558. https:\/\/doi.org\/10.1038\/s41591-018-0136-1 (2018).","journal-title":"Nat. Med."},{"key":"22002_CR51","doi-asserted-by":"publisher","first-page":"992855","DOI":"10.3389\/fimmu.2022.992855","volume":"13","author":"S Feng","year":"2022","unstructured":"Feng, S. et al. Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM. Front. Immunol. 13, 992855. https:\/\/doi.org\/10.3389\/fimmu.2022.992855 (2022).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22002-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22002-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22002-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:03:24Z","timestamp":1762549404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22002-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22002"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22002-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The patients\/participants [legal guardian\/next of kin] provided written informed consent to participate in this study. All research was performed in adherence to the principles outlined in the Declaration of Helsinki (1964) and was approved by the Ethics Committee of Henan Provincial People\u2019s Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"38306"}}